Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA AG    MRK   DE0006599905

MERCK KGAA AG

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : Backs 2019 View; Sees Profitable Growth Over Next Years

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/11/2019 | 02:02am EDT

By Max Bernhard

Germany's Merck KGaA (MRK.XE) on Wednesday backed its guidance for the year and said that it also expects profitable growth in the years to come.

"For 2019, we continue to assume that the group will increase all its key figures: sales, EBITDA pre and EPS pre. We also have our sights firmly set on profitable growth for 2020 and beyond," Chief Executive Stefan Oschmann said at the pharmaceutical company's capital markets day.

Merck also said that by 2022, it targets additional annual sales of around 2 billion euros with new medicines. Its Mavenclad and Bavencio drugs are expected to contribute significantly to this, it added.

The company said it aims for maintained above-market growth in its life-science business and for its performance materials unit to resume growth as of 2020.

Write to Max Bernhard at max.bernhard@dowjones.com; @mxbernhard

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA AG
09/12MERCK KGAA : Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation ..
AQ
09/11MERCK : Gets FDA Breakthrough-Therapy Designation for Tepotinib
DJ
09/11MERCK : Darmstadt, Germany, on Track to Deliver Sustainable Profitable Growth - ..
PU
09/11MERCK : Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for I..
PU
09/11MERCK : Darmstadt, Germany, on Track to Deliver Sustainable Profitable Growth
PU
09/11MERCK : Backs 2019 View; Sees Profitable Growth Over Next Years
DJ
09/10Merck Down Nearly 5%, on Pace for Largest Percent Decrease Since October 2017..
DJ
09/10MERCK : Darmstadt, Germany Initiates Pivotal Phase III Program for Investigation..
PU
09/09MERCK : Updated Results for Investigational Therapy Tepotinib Presented at WCLC ..
PU
09/04MERCK : David Alsteens Receives 2019 Heinrich Emanuel Merck Award for Analytical..
PU
More news
Financials (EUR)
Sales 2019 15 600 M
EBIT 2019 2 255 M
Net income 2019 1 476 M
Debt 2019 5 764 M
Yield 2019 1,32%
P/E ratio 2019 29,0x
P/E ratio 2020 23,0x
EV / Sales2019 3,13x
EV / Sales2020 2,88x
Capitalization 43 052 M
Chart MERCK KGAA AG
Duration : Period :
Merck KGaA AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 103,05  €
Last Close Price 99,18  €
Spread / Highest target 23,0%
Spread / Average Target 3,90%
Spread / Lowest Target -17,3%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA AG10.05%47 676
WUXI APPTEC CO LTD50.81%18 489
KYOWA KIRIN CO LTD1.38%10 209
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD15.45%8 429
JAZZ PHARMACEUTICALS PLC6.01%7 441
BETTA PHARMACEUTICALS CO LTD--.--%2 688